You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ALK Rearrangement

Showing 1 - 25 of 447
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ALK Phosphorylation Trial in Harbin (crizotinib for rearrangement-negative, high phosphorylated ALK patients)

Completed
  • ALK Phosphorylation
  • crizotinib for rearrangement-negative, high phosphorylated ALK patients
  • Harbin, Heilongjiang, China
    Harbin Medical University Cancer Hospital
Mar 19, 2023

Radiotherapy Side Effect, NSCLC, ALK Gene Mutation Trial in Stockholm (SBRT/SRS/radiation therapy)

Not yet recruiting
  • Radiotherapy Side Effect
  • +2 more
  • SBRT/SRS/radiation therapy
  • Stockholm, Sweden
    Karolinska University Hospital
Feb 16, 2023

NSCLC, Stage III, ALK-rearrangement Trial in Worldwide (Brigatinib, Durvalumab)

Not yet recruiting
  • NSCLC, Stage III
  • ALK-rearrangement
  • Angers, France
  • +19 more
Feb 8, 2023

ROS1 Rearrangement NSCLC, ALK Rearrangement NSCLC Trial in ShangHai (XZP-3621)

Recruiting
  • ROS1 Rearrangement Non-small Cell Lung Cancer
  • ALK Rearrangement Non-small Cell Lung Cancer
  • ShangHai, Shanghai, China
    Shanghai Chest hospital affiliated to Shanghai jiao tong univers
Sep 14, 2021

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in United States (NVL-655)

Recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Orange, California
  • +13 more
Jan 31, 2023

NSCLC, ALK Gene Rearrangement Positive Trial in United States (Ensartinib)

Available
  • Non-Small Cell Lung Cancer
  • ALK Gene Rearrangement Positive
  • Stanford, California
  • +3 more
Oct 18, 2022

NSCLC Trial in Worldwide (Capmatinib, Spartalizumab, Docetaxel)

Completed
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • Fayetteville, Arkansas
  • +7 more
Jan 21, 2022

NSCLC (NSCLC) Trial in China (Capmatinib)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Xiamen, Fujian, China
  • +18 more
Jan 27, 2023

NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation Trial in France (Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab,

Recruiting
  • NSCLC Stage IIIB
  • +4 more
  • Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab
  • Carboplatin + Pemetrexed + Atezolizumab
  • Angers, France
  • +30 more
Jun 7, 2021

Lung Tumors Trial in France (ALK analysis on CTCs detected by ISET)

Completed
  • Lung Neoplasms
  • ALK analysis on CTCs detected by ISET
  • Caen, France
  • +10 more
Dec 7, 2020

Nsclc, EGFR Activating Mutation, EGF-R Positive NSCLC Trial in Hong Kong (Pembrolizumab, Lenvatinib, Pemetrexed)

Recruiting
  • Nsclc
  • +5 more
  • Hong Kong, Hong Kong
    Queen Mary Hospital
Nov 25, 2021

NSCLC, Crizotinib, ALK Gene Rearrangement or ROS1 Gene Rearrangement Trial in France

Completed
  • NSCLC
  • +2 more
    • Aix en Provence, France
    • +25 more
    Sep 24, 2021

    ALK Gene Rearrangement Positive, Non-Squamous Non-Small Cell Tumor of Lung Trial in Mexico City (Alectinib, Bevacizumab)

    Unknown status
    • ALK Gene Rearrangement Positive
    • Non-Squamous Non-Small Cell Neoplasm of Lung
    • Mexico City, Mexico
      Instituto Nacional de Cancerologia
    Feb 8, 2021

    Mature B-Cell Tumor, Non Hodgkin Lymphoma, DLBCL Trial (SGR-1505)

    Not yet recruiting
    • Mature B-Cell Neoplasm
    • +25 more
    • (no location specified)
    Sep 14, 2022

    NSCLC, ALK Gene Rearrangement Positive Trial in France (RNAseq)

    Recruiting
    • Non-small Cell Lung Cancer
    • ALK Gene Rearrangement Positive
    • RNAseq
    • Saint-Denis, La Réunion, France
    • +44 more
    Nov 4, 2021

    Plasma NGS for Assessment, Characterization, Evaluation of ALK

    Active, not recruiting
    • Non-Small Cell Lung Cancer
    • Plasma Next Generation Sequencing (NGS)
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Jan 26, 2023

    ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Pure

    Completed
    • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Sep 23, 2021

    Non Small Cell Lung Cancer, Stage IV NSCLC, Recurrent Non Small Cell Lung Cancer Trial in Tampa (biological, drug, other)

    Recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • Tumor-infiltrating Lymphocytes (TIL)
    • +5 more
    • Tampa, Florida
      Moffitt Cancer Center
    Dec 28, 2022

    ALK Positive NSCLC Trial in Guangzhou (Loratinib)

    Recruiting
    • ALK Positive Non-small Cell Lung Cancer
    • Guangzhou, Guangdong, China
      Guangdong Provincial Perople's Hospital
    Oct 19, 2023

    ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The

    Completed
    Has Results
    • Non-small Cell Lung Cancer
      • Cairo / Misr Al Qadimah, Egypt
      • +10 more
      May 14, 2019

      First Line Crizotinib for ALK Rearranged Non-squamous Non-small

      Recruiting
      • Non-small Cell Lung Cancer
      • Changsha, Hunan, China
        Hunan Cancer Hospital
      Mar 1, 2022

      NSCLC Trial in Guangzhou (Avitinib Maleate, Afatinib, Crizotinib)

      Recruiting
      • Carcinoma, Non-Small-Cell Lung
      • Avitinib Maleate
      • +13 more
      • Guangzhou, Guangdong, China
        Guangdong Lung Cancer Institute, Guangdong Provincial People's H
      Dec 3, 2022

      Non Small Cell Lung Cancer Trial in Goyang-si (Brigatinib)

      Recruiting
      • Non Small Cell Lung Cancer
      • Goyang-si, Gyeonggi-do, Korea, Republic of
        National Cancer Center
      Apr 4, 2022

      China With Non-Small-Cell Lung Cancer That is Unable to be

      Not yet recruiting
      • Carcinoma, Non-Small-Cell Lung
        • (no location specified)
        May 16, 2023

        Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression Trial in Worldwide (Data collection and quality of life

        Recruiting
        • Cancer
        • +15 more
        • Data collection and quality of life questionnaire
        • Graz, Austria
        • +40 more
        Jul 27, 2021